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Gap junction proteins (connexins) are differentially expressed throughout the multiple layers of the
epidermis. A variety of skin conditions arise with aberrant connexin expression or function and sug-
gest that maintaining the epidermal gap junction network has many important roles in preserving
epidermal integrity and homeostasis. Mutations in a number of connexins lead to epidermal dyspla-
sias giving rise to a range of dermatological disorders of differing severity. ‘Gain of function’ muta-
tions reveal connexin-mediated roles in calcium signalling within the epidermis. Connexins are
involved in epidermal innate immunity, inﬂammation control and in wound repair. The therapeutic
potential of targeting connexins to improve wound healing responses is now clear. This review dis-
cusses the role of connexins in epidermal integrity, and examines the emerging evidence that con-
nexins act as epidermal sensors to a variety of mechanical, temperature, pathogen-induced and
chemical stimuli. Connexins thus act as an integral component of the skin’s protective barrier.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Overview topographical niches, with a ﬁne balance between commensalThe mammalian epidermis forms a resilient, water-imperme-
able barrier that protects internal organs from the external envi-
ronment. This highly differentiated, stratiﬁed structure consists
of basal, spinous, granular and corniﬁed keratinocyte layers that
are characterised by the differential expression of keratins and a
range of cell-to-cell adhesion and junctional proteins, including
the connexins (Fig. 1) [1]. This barrier provides an interface with
the external environment, the surface of which is colonised by a
diverse array of microorganisms that exist in specialisedand potentially opportunistic pathogenic organisms [2]. Disruption
in the balance of this host–microbe interaction can result in skin
disorders and infection [3]. In recent years, observed changes in
connexin expression and signalling in a number of epidermal con-
ditions have indicated a central role for connexin-mediated events
in maintaining the integrity of this tissue. This review focuses on
recent evidence supporting the concept that the epidermal conn-
exin network plays a central role in sensing and maintaining epi-
dermal integrity, and that connexins are emerging as prime
therapeutic targets for a diverse range of epidermal conditions.
2. Connexins and the epidermis
Connexins are a family of highly conserved transmembrane
proteins that assemble to form connexon hemichannels in the cell
plasma membrane. Under ‘normal’ conditions these channels are
closed, however they can be triggered to open under environmen-
tal stress conditions, providing a conduit between the intra- and
extra-cellular environments. Ultimately, connexons align and dock
with connexons from neighbouring cells to form dodecameric gap
junction channels, which facilitate the direct exchange of inorganic
ions, small metabolites and cellular messenger molecules (<1 kDa
in size) between cells [4,5]. Twenty-one connexin subtypes have
Fig. 1. Representative image of expression proﬁle of key connexins in normal human epidermis. Of note Cx26 is generally expressed at very low levels in normal epidermis
but is enhanced under a range of hyperproliferative skin disorder. Mutations in Cx26, Cx30 and Cx31 are associated with hyperproliferative skin disorders falling into two
main groupings: ‘loss of function’ or ‘gain of function’. These mutations give insight into the functional role of connexins in epidermal integrity. See text for details.
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according to their phylogenetic origins into the ‘alpha’ subgroup
connexins (including connexin43 (Cx43), Cx40 and Cx45) and the
‘beta’ subgroup connexins (including Cx26, Cx30 and Cx31), each
having unique tissue expression patterns and permeability proper-
ties [4,6]. In the stratiﬁed, avascular epidermis these proteins pro-
vide a mechanism for cells to co-ordinate their activities.
The integrity of the epidermal barrier is maintained by contin-
uous renewal of the cell layers from a pool of epidermal stem cells,
with a steady state existing between the rate of production of new
cells in the basal layer and the rate of loss of terminally differenti-
ated cells from the skin surface [7]. Up to 10 different connexin
proteins are differentially expressed throughout the terminal dif-
ferentiation programme [8], with Cx43 the main connexin found
in basal proliferating cells. In the human epidermis connexin
expression is at its highest in the spinous layer with the expression
of Cx26, Cx30, Cx30.3, Cx31, Cx31.1, Cx40, Cx43 and Cx45, and in
the granular layer where there are high levels of Cx30.3, Cx31
and Cx43 and lower levels of Cx26, Cx31.1, Cx40 and Cx45,
although species-speciﬁc variations occur [9–11] (Fig. 1).
The role of these proteins in establishing and maintaining the
epidermal barrier is signiﬁcant as exempliﬁed by the many skin
states and diseases associated with altered connexin expression
and mutations in Cx43, Cx31, Cx31.1 Cx30.3, Cx30 and Cx26 (re-
viewed by [12,13]). During wound healing, distribution patterns
of both Cx43 and Cx26 are remodeled, and Cx43 emerges as a ther-
apeutic target to improve wound closure events (reviewed by
[14]). Of particular interest is Cx26, the shortest connexin, which,
although abundant in other stratiﬁed epithlia, e.g. vagina and oral
cavity, is generally found at low levels throughout the stratiﬁed
epidermis. Expression of Cx26 is enhanced in a range of hyperpro-
liferating skin disorders including chronic non-healing wounds
[15], psoriasis [16], and in human papilloma virus (HPV)-induced
cutaneous warts [17]. It is also upregulated in the early stages of
HPV16-associated cervical cancer progression [18], although
downregulated in advanced stages [19]. Certain dominant-acting
mutations in Cx26 manifest in distinctive skin disorders that range
from mild to lethal forms, leading to suggestions that maintaining
the Cx26 balance is crucial for epidermal integrity.
3. Mutations in connexins and epidermal dysplasia
Many mutations in Cx26 are present in the human population,
with recessive mutations throughout the Cx26 coding region now
recognised as one of the most common genetic causes of non-syn-
dromic hearing impairment (NSHI) [20], and genetic screening for
Cx26 mutations is often offered (e.g. http://www.arupconsult.com/
Topics/NSHL.html#tabs=2). Cx26 mutations are believed to have
remained in the gene pool due to heterozygous advantage, possibly
by improving epithelial barrier function (see below) [21]. Patients
harbouring recessive mutations, or extensive Cx26 gene deletions,suffer from deafness but no skin pathology, suggesting that Cx26 is
not an absolute requirement in human skin, although epidermal
thickening of carriers has been reported [22,23]. This is exempli-
ﬁed by the 35delG mutation, which is the highest penetrating
Cx26 mutation. It is highly likely that in the absence of Cx26
expression, substitution by the closely related Cx30 carries some
of the responses, as reported in studies using mouse models of
the cochlea [24,25].
In addition to deafness, a spectrum of skin disorders is associ-
ated with autosomal dominant Cx26 mutations. Autosomal domi-
nant mutations in other beta connexins including Cx31, Cx30 and
Cx30.3 are also linked with unique epidermal dysplasias, while
up to 73 mutations in Cx43 are associated with oculodentodigital
dysplasia (ODDD) (recently reviewed by [26]), that along with
other tissue defects sometimes manifests in palmar plantar hyper-
keratosis. The impact of these mutations on connexin assembly
and function are beginning to provide clues as to the functional
importance of the connexin family in the epidermis.
To understand the role of connexins in the epidermis it is impor-
tant to ﬁrst consider the key steps in the connexin life cycle. Transla-
tion of connexin mRNA occurs on endoplasmic reticulum (ER)-
bound ribosomes, ensuring co-translational insertion into themem-
brane enabling the protein to adopt its correct topology. Four trans-
membrane domains are linked by two extracellular loops (E1 and
E2), which project into the lumen of the ER, with intracellularly-lo-
cated amino and carboxyl termini and a linking intracellular loop.
Six connexins then oligomerise in the ER/Golgi environs to form a
connexon hemichannel [27,28], which is trafﬁcked in a closed state
to the plasma membrane via a microtubule-dependent pathway
with the aid of plus end motor proteins [27,29,30] and chaperones
such as consortin [28] and CIP75 [31]. It is important to note that al-
pha and beta connexin subtypes are incompatible and are unable to
form heteromeric channels [6]. The beta connexins Cx26 and Cx30
have also been reported to be recruited to the plasma membrane
via a microtubule-independent route, bypassing the classical secre-
tory pathway [32,33]. Once inserted into the plasma membrane,
hemichannels laterally accrete and dock with hemichannels on the
neighbouring cell at the edge of an established gap junction intercel-
lular plaque [34]. Close association of the carboxyl terminal domain
of the mature connexin protein with cytoskeletal adaptor proteins
including zona occludens 1 (ZO-1) at the plasma membrane
[35,36] and post-translational modiﬁcation (particularly for Cx43)
suggest that connexins are also involved in cell migration and cell-
to-cell adhesion responses [37–40]. The beta connexins, particularly
Cx26andCx30,with short carboxyl termini, are less likely tobepost-
translationally modiﬁed on their carboxyl termini and Cx30 has
been reported to lack any interactions with ZO-1 [33]. The connexin
life cycle is typically short (with a half-life of 2–4 h), such that new
connexons are continuously added to the edges of the plaque and
old connexons are removed from the central region by
invagination into one cell and formation of a connexosome [5] that
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lysosomal degradation pathways [28]with autophagy playing a role
[41,42].
Mutations in connexins can affect any one of these biogenic
steps with the consequences now aiding functional dissection of
the roles of speciﬁc domains in protein function. Among the auto-
somal dominant mutations associated with beta connexins, a
genotype-phenotype correlation is emerging, as mutations tend
to fall into two key groupings that can be categorised into ‘loss
of function’ or ‘gain of function’ mutations, the latter being associ-
ated with the most severe epidermal disorders.4. ‘Loss of function’ mutations and epidermal integrity
Cx26 loss of function mutations identiﬁed to date map to the
distal E1 and E2 domains and are associated with non-inﬂamma-
tory hyperproliferative skin disorders that cause distinct diseases,
but share the characteristics of palmoplantar hyperkeratinisation
(PPK) and deafness (reviewed by [12]). The most widely recognised
of these syndromes is Vohwinkel syndrome (OMIM#124500)
caused by mutations D66H [43] and Y65H [44] located on the dis-
tal domain of the ﬁrst extracellular loop. The disease is character-
ised by a distinctive starﬁsh or honeycomb-like keratoderma with
constriction bands encircling the phalanges of ﬁngers and toes,
ultimately resulting in autoamputation of the digits [43]. A trans-
genic mouse model reﬂects the human condition; animals lose
their tails through auto-amputation within three weeks of birth
[45] thereafter living long and healthy lives (frequently to 2 years)
with no further skin abnormalities (Martin et al., unpublished
observations). Electrophysiological voltage gating assays in Xeno-
pus oocytes and/or dye transfer assays in HeLa cells transfected
to express the mutation reveal non-functional gap junction and
hemichannel formation [11,44,46] while immunocytochemical
analysis determine that the protein is restricted to the ERGIC re-
gion of the cell, suggesting trafﬁcking insufﬁciency [44,45]. Co-
expression with Cx30, but not Cx43, is reported to rescue the traf-
ﬁcking defect, but the resulting channels remained non-functional
[45]. A number of other mutations in Cx26 giving rise to PPK-re-
lated syndromes result in loss of function and intracellular restric-
tion, including H73R [47], S183F [48], R75W and R75Q [49]. All of
these mutations show reduced gap junction permeability, while
several of these are reported to exhibit transdominant inhibition
of wild type Cx26 [50]. Interestingly, a Cx26 R75Y mutation, that
has lost hemichannel activity but retained Cx26 gap junction cou-
pling, has revealed novel insights into the role of Cx26 gap junc-
tions in selective suppression of cell growth by mediating cAMP
transfer. The data points towards Cx26 being an important signal-
ling conduit for limiting the rate of cell cycle progression in cancer
cell lines [39]. Whether defective cAMP signalling plays a role in
the context of the pathology of connexin-related PPK skin disor-
ders raises intriguing future questions.
As mentioned above these disorders are all classiﬁed as non-
inﬂammatory hyperproliferating disorders. Whether the lack of
Cx26 function or intracellular accumulation of the aberrant protein
are key steps in the pathology remain unresolved, although the
involvement of ER stress and unfolded protein responses are likely
[51,52]. Given that the heteromeric channels also have restricted
permeability, defective gating may be a linking theme, and sug-
gests that despite the low level of Cx26 in normal human epider-
mis, regulation of Cx26 activity has an important role.5. ‘Gain of function’ mutations and epidermal integrity
Over the last few years studies into the functional consequences
of ‘gain of function’ mutations have yielded signiﬁcant informationand clues as to the importance of connexins in epidermal integrity.
Two syndromes, keratitis ichthyosis deafness (KID)
(OMIM#148210), caused by mutations in Cx26, and erythrokerato-
dermia variabilis et progressiva (EKV-P) (OMIM#133200), caused
by mutations in Cx31 will be considered.
KID syndrome, a rare ectodermal dysplasia with about 100 re-
ports to date, is the severest connexin-related skin disorder and
is characterised by sensorineural hearing loss, hyperkeratosis of
the palms and soles, erytherokeratoderma on the extremities and
face, follicular hyperkeratosis, photophobia and corneal vasculari-
sation that ultimately leads to blindness. Patients are also more
prone to Gram positive bacterial and fungal skin infections (see be-
low) and many have a predisposition to squamous cell carcinoma
(examples of case reports include [53–59]). The causative Cx26
mutations for KID syndrome map to the N-terminus (G12R,
N14K, S17F), the proximal E1 domain (A40V, G45E, D50N, D50Y,
D50A) and there is one report in the second transmembrane do-
main (A88V) of the Cx26 protein (reviewed by [12,13]). There are
subtle differences between the phenotypes associated with KID
mutations; D50N is the most common mutation, while G45E and
A88V are associated with lethal forms [54,60].
Several mouse models for KID, tailored to express relevant Cx26
mutations in the epidermis, exhibiting differing degrees of sever-
ity, have been reported. A G45E model presents with a lethal form
of KID with transgenic mice displaying reduced viability, hyperker-
atosis and hair loss [61]. A model expressing the S17F mutation un-
der the control of the endogenous Cx26 promoter produces
homozygous animals that are non-viable and surviving heterozy-
gous offspring show hyperplasia of the tail and foot epidermis
and are smaller than their litter mates with many symptoms of hu-
man KID syndrome [62]. A further report of a G12Rmodel, with the
mutant Cx26 under the control of the cytokeratin 10 promoter,
(using the same gene cassette as that reported for the Vohwinkel
syndrome mouse [45]), reveals that animals presenting with the
syndrome develop a late onset disease, are smaller than their litter
mates and have kinks on their tails. The animals are prone to
hyperproliferative skin complications, hair loss, skin infection
and development of tumours [63]. Characterising the spatial local-
isation and gating characteristics of these mutations has led to pro-
found advances in our understanding of the role of connexins in
epidermal integrity at several levels.
KID syndrome mutations (e.g. G12R, D50N, N14K [64,65]) are
reported to target to the plasma membrane and localise at discrete
punctate regions rather than being incorporated into large gap
junction plaque-like areas. Intracellular retention has been re-
ported in other KID mutations (e.g. S17F) [62]. Electrophysiological
gating experiments in Xenopus oocytes expressing KID mutants
indicate reduced resistance indicative of open hemichannels [66].
Further electrophysiological studies in Xenopus oocytes, illustrate
that KID mutants form leaky hemichannels that are sensitive to
low extracellular calcium levels and can be blocked by elevated
calcium [67]. In mammalian cells, hemichannel activity can be trig-
gered by low extracellular calcium conditions and observed by
monitoring ATP release in the presence and absence of hemichan-
nel blockers such as carbenoxolone and connexin mimetic peptides
[68,69]. In HeLa cell-based assays KID mutations respond dramat-
ically to a low extracellular calcium switch releasing ATP; a
response not seen in ‘loss of function’ mutations [11]. A conse-
quence of open hemichannel activity is release of secondary mes-
sengers from the cells, including ATP, which has subsequent
effects on downstream purinergic signalling pathways (see below).
The level of extracellular calcium sensitivity seems to equate to the
lethality of the condition, with mutations such as D50A, associated
with a mild form of KID, being less sensitive to low extracellular
calcium levels than A88V and G45E mutations that are associated
with lethal KID [70]. Understanding of Cx26 structure [71] has
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tein domains and provides further clues as to the reasons for func-
tional defects [72]. Further, under normal physiological conditions
KID mutants expressed in HeLa cells spread dye more extensively
to their neighbours than wild type Cx26 [64] [65], again re-enforc-
ing the fact that the KID channels formed are unstable, leaky or
easily triggered by environmental challenge [13,72]. The fact that
ATP release can be inhibited by a range of connexin channel block-
ers, leads to the suggestion that tailored Cx26 therapeutics hold
translational value [11,72].
6. ‘Gain of function’ mutations illustrate a role for connexin
signalling in calcium homeostasis
The intra/extra-cellular calcium balance plays a profound role
in regulating keratinocyte differentiation and formation of the epi-
dermal barrier. A steep calcium gradient exists in the epidermis,
with the calcium concentration increasing as cells differentiate
[73,74]. Disruption of this gradient leads to increased proliferation
and aberrant differentiation [73]. The calcium-sensor receptor
(CaR), expressed in the suprabasal layers, plays an important role
in promoting cell differentiation and enabling cells to respond to
changes in epidermal calcium levels. Recent evidence indicates
that the CaR enables translocation of E-cadherin and RhoA to the
plasma membrane, thereby permitting the formation of strong cal-
cium-induced cell–cell adherens junctions, and interactions with
b-catenin and the junctional nexus [75]. From the observations of
Cx26 KID mutants, it is evident that regulation of connexin hemi-
channel activity is crucial in these events. The extracellular do-
mains of connexins are highly conserved, and of these, position
G45 in the proximal E1 domain is particularly conserved. The
Cx26G45E mutation manifests as the severest form of KID
[54,58] and this site is also associated with a calcium binding do-
main in Cx32 [76]. Elegant studies by Zhang and colleagues [77],
determined that introducing the G45E mutation to Cx30 or Cx26
results in enhanced hemichannel activity and ultimately leads to
cell apoptosis and death that can be rescued by increased extracel-
lular calcium. By contrast, while Cx43 and Cx32 G45Emutations do
not induce lethal effects the hemichannel response to extracellular
calcium is more sensitive than wild type counterparts, suggesting
that the E1 domain G45 position represents an important calcium
sensor [77].
Mutations in the closely related Cx31 are associated with EKV-
P, a rare disease characterised by ﬁxed hyperkeratotic plaques and
transient erythema [78]. A mouse model for the Cx31F137L muta-
tion is reported to reﬂect the human skin phenotype [79]. A com-
mon theme among Cx31 mutations is abnormal protein trafﬁcking
with the mutant protein accumulating in intracellular locations
and resultant apoptotic or necrotic cell death [52,80,81]. Some of
these mutations are reported to induce ER stress, including muta-
tions Cx31C86S, G12D and R42P, as determined by upregulation of
proteasomal and unfolded protein response (UPR) proteins such as
BiP/GRP78 (binding immunoglobulin protein/glucose-regulated
protein of 78 kDa). These data suggest that ER stress rather than
aberrant channel function is a major cause of necrotic cell death
[52,82]. Further, recent studies suggest that in cells expressing
the mutation Cx31R42P, the induced ER stress promotes produc-
tion of reactive oxygen species (ROS), which in turn has conse-
quences on hemichannel activity, with scavengers of ROS
preventing Cx31R42P cell death and hemichannel activity [83].
van Steensel and colleagues have recently identiﬁed a rare
Cx31G45E mutation associated with EKV-P [84]. The functional
implications of this mutation remain to be resolved; with the
mutation introducing gross defects in Cx31 trafﬁcking and the
induction of necrotic cell death that is not completely rescued byblocking channel activity [84]. Given the observations by Zhang
et al. [77] it is highly plausible that sensitivity to calcium levels
at this site are a major factor in EKV-P pathophysiology.
7. Connexins, ATP release and purinergic signalling
A common theme with both EKV-P and KID syndrome, unlike
the ‘loss of function’ Cx26 mutations, is that they give rise to
inﬂammatory skin disorders. Over-active hemichannels, stimu-
lated by environmental factors to release secondary metabolites
such as ATP, will have profound consequences on downstream sig-
nalling events, epidermal integrity and inﬂammatory-mediated
consequences. A critical signalling molecule released into the
extracellular space by connexins is ATP. This plays a pivotal role
in transmitting and activating purinergic cell signalling pathways
implicated in a diverse array of processes, including innate im-
mune responses, inﬂammation, pain, cell proliferation, differentia-
tion and cell death [85,86]. Within the skin, the P2X7 receptor
pathway plays an important role in epidermal barrier function
and inﬂammatory-mediated events [86,87]. The P2X family of
receptors are ligand-gated ion channels activated by extracellular
ATP, eliciting a ﬂow of cations across the plasma membrane with
the P2X7 receptor having the lowest afﬁnity for ATP (Ec50 300–
400 lM ATP). P2X7 is largely regarded as a non-selective ion pore
associated with calcium entry, inﬂammosome recruitment and cell
death [86]. Recently, pannexin 1 (Panx1), a protein closely related
to connexins, which also forms hexameric hemichannels, was
identiﬁed as a non-selective large conductance pore closely linked
with P2X7 receptor signaling. These two proteins are now believed
to be involved jointly in cell permeabilisation providing a large
pore associated with ‘ﬁnd me’ signals [88]. Activation of the
P2X7/Panx1 receptor signalling pathway ultimately leads to intra-
cellular calcium mobilisation, induction of cytokine expression
and apoptotic cascades [89]. In the skin, inﬂammatory-mediated
events are associated with ATP release and increased P2X7 signal-
ling (reviewed by [86]).
P2Y2 receptors, G-coupled receptors that activate inositol tri-
phosphate (IP3) signalling pathways, also mediate keratinocyte
proliferation [90]. Indeed, recent evidence suggests that ATP re-
lease via connexin hemichannels can inﬂuence P2Y2 receptor sig-
naling in cardiac ﬁbroblasts [91]. Generation of IP3 (for which
gap junctions are key conduits) is known to promote cell prolifer-
ation and inhibit differentiation, and P2Y2 receptors are normally
resident in the basal epidermal layers where the majority of prolif-
eration occurs. By contrast P2X7 receptors targeted by ATP tend to
be located in the upper layers and are associated with differentia-
tion (reviewed by [86]). Importantly, Panx1 and Panx3 are also ex-
pressed in keratinocytes with emerging roles in epidermal
differentiation and integrity recently being identiﬁed [92,93].
Thus induction of purinergic signalling can have profound im-
pact on epidermal integrity. External environmental stimuli,
including mechanical stimulation, chemo- and thermo-sensitivity,
that activate connexin hemichannel signalling, are described as
triggering purinergic signalling. Reports also suggest that Cx26
and the EKV-P mutation Cx31R42P form hemichannels that are
temperature sensitive [82,94], which is also an interesting observa-
tion in context with continuous exposure of the epidermis to ﬂuc-
tuations in temperature. Within the epidermis, differentiating
keratinocytes are surrounded by numerous sensory nerve endings
that play an important role in tactile sensation and nociception
[95]. Air exposure of keratinocytes, required for stratiﬁcation, is
proposed to induce ATP release via connexin hemichannels [96].
This can subsequently inﬂuence purinergic signalling pathways in-
volved in induction of chronic pain and cell proliferation/differen-
tiation. This is an intriguing observation that lends to a further role
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report an association of pain with alterations in connexin expres-
sion/function [97,98] and further investigations using animal mod-
els are warranted. Such studies indicate that topical application of
connexin channel inhibitors may be of beneﬁt in chronic pain con-
ditions [96,99].
In addition, Cx26 has recently been implicated as a CO2 sensor
in the respiratory system; Dale and colleagues have shown that
Cx26 hemichannels are responsive to changes in pCO2 that contrib-
ute to respiratory chemo-sensitivity [100,101]. Future studies may
determine the sensitivity of these channels in deﬁned tissue net-
works such as the skin. Indeed, it is likely that the transcutaneous
CO2 environment is similar to that reported for the respiratory sys-
tem and may change through the epidermal layers.
Connexins thus emerge to act as direct and indirect epidermal
sensors to mechanical, temperature, and chemical-induced stimu-
lation, conveying information via the skin to allow the internal
environment to react swiftly to changes in the external
environment.8. Connexins, the skin microﬂora and innate immunity
It is noteworthy that the major cause of death of KID syndrome
patients harbouring ‘lethal mutations’ is severe septicemia caused
by infection with opportunistic pathogens, including Staphylococ-
cus aureus, Pseudomonas aeruginosa and Candida sp. (e.g. [58]). Pa-
tients harbouring milder mutations suffer from chronic skin
infections suggesting a shift in the balance of commensal to oppor-
tunistic skin ﬂora [53–55,102,103]. Susceptibility to microbial skin
infection has not been reported or observed in patients with other
connexin channelopathies (van Steensel, personal communication,
clinical observations) providing some further clues about geno-
type–phenotype relationships.
The skin surface is a rich ecosystem of microbial communities
that live in varied pathophysiological and topographical niches
[2]. The distinction between harmless ﬂora and pathogenic organ-
isms is often dictated by the skin’s ability to resist infection and not
the inherent properties of the microbe itself [2]. A disturbance of
epidermal barrier function and/or innate immunity may predis-
pose the host to a number of cutaneous infections and inﬂamma-
tory diseases [3]. Mounting evidence suggests that aberrant Cx26
expression and/or function may contribute to such disturbance
(see below). Recent studies determined that Staphylococcus epide-
rmidis, a normal resident of the healthy human skin, has a mutually
beneﬁcial relationship with keratinocytes as it produces inhibitors
active against opportunistic pathogens including S. aureus, Strepto-
coccus sp. and some fungal pathogens [104,105]. Indeed, several re-
ports have indicated that S. epidermidis, or puriﬁed peptidoglycan
(PGN) (a major component of the Gram positive cell wall and
pro-inﬂammatory agent), does not induce an innate immune re-
sponse in keratinocytes. By contrast PGN isolated from S. aureus
evokes a potent interleukin 6 (IL-6) response [64,104].
The impact of pathogens on connexin-mediated events in trig-
gering innate immune responses with highly tissue-speciﬁc conn-
exin subtypes is becoming clear in numerous tissues, including the
epidermis [64], endothelium [106] and gut epithelia [107,108] (re-
cently reviewed by [109,110]). In keratinocytes, PGN challenge
from S. aureus, but not S. epidermidis induces Cx26 expression with
limited effect on Cx43 expression [64]. This is in contrast to endo-
thelial cells where exposure to PGN from both organisms increases
Cx43 expression and induces both toll-like receptor 2 (TLR2) and
IL-6 expression. These events are linked to acute induction of conn-
exin hemichannel activity and can be inhibited by exposure to a
range of connexin channel blockers, including the connexin
mimetic peptide Gap26 [106]. Examining the impact of PGN fromS. aureus and S. epidermidis on KID and non-KID mutant channel
activity and downstream responses in keratinocytes reveals that
PGN from the opportunistic pathogen acutely induces hemichan-
nel signalling releasing signiﬁcantly more ATP and IL-6 from the
cells than those transfected to express wild type Cx26 and non-
KID mutants; these events are blocked by co-exposure to a connex-
in channel blocker [64]. These data start to provide an explanation
why ‘loss of function’ mutations are linked with non-inﬂammatory
disorders of the skin. In parallel studies, Kelsell and colleagues
have observed that non-functional Cx26 mutations associated with
NSHI confer resistance to enteric infections such as Shigella ﬂexneri
[21,111]. The effect of S. ﬂexneri is mediated via cellular invasion,
shown to activate Cx26 hemichannel signalling [108,112]. Cells
expressing Cx26 mutations associated with NSHI exhibit reduced
levels of infection [21] and inhibition of Cx26 expression with siR-
NA in a human intestinal cell model reduced the ability of S. ﬂexneri
to invade the cell [111]. Such studies further support the concept of
Cx26 being a potential therapeutic target to control gastrointesti-
nal bacterial infection [108,111]. Increasingly, there is linkage be-
tween the impact of gut and skin ﬂora on cellular events [113]
and these studies also support the notion that recessive Cx26
mutations have remained in the population due to heterozygous
advantage [21,114]. Indeed, with the advent of microbiome studies
it will be interesting to compare the skin and gut ﬂora of distinctive
Cx26 populations.
A further skin condition associated with Cx26 gain of function is
psoriasis. This is a chronic hyperproliferating skin disorder that
manifests as sporadic psoriatic plaques or skin lesions that are
characterised by loss of the granular layer and incomplete kerati-
nocyte differentiation associated with a thickened corniﬁed layer
[115]. Enhanced Cx26 expression has long been associated with
this and associated disease states [16,17,116] and in recent years
Cx26 has emerged as a marker for psoriasis [117,118]. Interest-
ingly, decreased expression of Cx43 and associated adhesion pro-
teins, including E-cadherin, beta catenin and tight junction
proteins, are also hallmarks of the disease [119–121]. There is
much contention as to whether psoriasis is an ‘outside-in’ or an ‘in-
side-out’ epidermal disorder, although recruitment of T-cells and
dendritic cell responses are undoubedly key events [122]. How-
ever, it remains plausible that the epidermal keratinocytes are
not simply passive targets of an abnormal immune response [3].
It is interesting to note that changes in the skin ﬂora are highly evi-
dent in psoriatic plaques [3,123] and one might postulate that this
may be involved with triggering the enhanced Cx26 expression
and function. Disruption of the skin barrier by tape stripping in
murine models suggests that barrier defects encourage colonisa-
tion of S. aureus by favouring cell adherence and promoting local-
ised inﬂammation [124]. A correlation between the extent of
barrier disruption, severity of the psoriatic lesion and localised
inﬂammation is well established in psoriasis [125]. How the im-
pact of aberrant Cx26 expression in the skin relates to this remains
to be explored.
In light of such studies, a mouse model has been generated with
Cx26 expression placed under the control of the involucrin pro-
moter (inv-Cx26), thereby enhancing Cx26 expression in the gran-
ular layer. This results in stimulated hyperproliferation, gross
barrier deﬁciency and promotion of a psoriasiform response
[126]. Enhanced ATP release from keratinocytes isolated from the
inv-Cx26 expressing mice compared to wild type mice that can
be blocked with hemichannel blockers is evident.
It is also important to note that purinergic signalling (discussed
above) is involved in the pathology of psoriasis. Keratinocytes con-
tinuously release a basal level of ATP, irrespective of skin damage.
Elevated levels of ATP induce proliferation in HaCaT cells (a human
keratinocyte cell line), and this has been suggested to be a mecha-
nism through which hyperproliferation is induced in psoriasis
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be involved in triggering such purinergic signalling events and sug-
gests that controlling overactive hemichannel activity could be of
therapeutic beneﬁt.
Another condition related to skin infection and changes in Cx26
expression is HPV infection, associated with the development of
warts [17]. HPV manifests itself in basal keratinocytes where it re-
mains latent and is triggered to undergo replication upon keratino-
cyte differentiation, inducing changes in the epidermis resulting in
cutaneous wart formation [128]. Interestingly, KID syndrome pa-
tients are not more prone to HPV infection than ‘normal’ individu-
als [59], despite the evidence that they are more susceptible to
bacterial infections and squamous cell carcinoma.
Whether ATP release and hemichannel activity are important in
such epidermal viral-induced states remains to be explored. How-
ever, a critical role for gap junction communication eliciting the
bystander effect during viral infection has recently been reported
[129]. The role of gap junction channels in mediating secondary
messengers such as IP3 and cAMP are well established. Recently
gap junctions have been identiﬁed as key conduits for the second-
ary messenger cGAMP(20–50). This molecule is synthesised by the
enzyme cyclic GMP-AMP synthase (cGAS) that senses cytosolic
DNA, largely contributed by dsDNA viruses. Upon transmission to
neighbouring cells cGAMP(20–50) activates the ER-resident receptor
STING (stimulator of interferon genes), which is involved in induc-
ing an antiviral state [129]. This initial report opens a whole new
dimension in connexin signalling pathways driven within tissue
networks. With the epidermis acting as a key barrier to the exter-
nal environment, probing this pathway and the role of connexin
signalling in it, will be crucial in conﬁrming novel roles for connex-
in signalling in epidermal innate immune defense and integrity.
9. Connexins and epidermal repair
From the discussions above it is evident that a range of environ-
mental factors and mutations in connexins inﬂuence epidermal
physiology. A key function of the epidermis is to form a protective
barrier and if this is breached it must be rapidly repaired through a
series of classical wound healing events that are fully described
elsewhere [130,131]. It is now well established that as a conse-
quence of epidermal injury the epidermal gap junction network
at the wound edge is rapidly remodelled and that this is associated
with the onset of migration of cells into the wounded gap [15,132–
134]. Cx43 is a key player in orchestrating wound healing events
(recently reviewed by [14]). Cx43 expression at wound margins
declines rapidly (within 2 h) following injury, returning to normal
levels following re-epithelisation. Cx26, Cx30, Cx31 and Cx31.1
have also been shown to follow this pattern of expression during
wound healing [132,133,135]. Cx43 knockout mice have enhanced
wound closure times [133], and wounded keratinocytes from
ODDD Cx43 mutant mice display increased proliferation and dif-
ferentiation, although wound closure rates in these mice are unaf-
fected [136]. At the wound edge, Cx43 relocalises to intracellular
areas of the cell from the plasma membrane following wounding,
ready for rapid re-mobilisation back to the membrane when re-
quired. Cx43 expression further behind the wound edge is retained
preserving communication [15] [137]. The reduction of Cx43 at
wound edges allows cells to enter a migratory phase, where cell-
to-cell adhesion and cell adhesion to the extracellular matrix
(ECM) abates, and cell motility increases [69]. Keratinocytes mi-
grate over the injured area and proliferation behind the wound
edges is stimulated thereby increasing cell numbers to replace
those moving into the wound. Connexin functionality in these
reforming epithelial sheets is also reduced, as demonstrated in
mouse organotypic models [134] (Fig. 2).During wound closure Cx43 is also altered post-translationally.
Phosphorylation allows Cx43 function to change rapidly in re-
sponse to events such as hypoxia or injury. Protein kinase C
(PKC) phosphorylation of Cx43 at position ser368 is present in
unwounded epidermis, but 24 h after wounding, the level of
Cx43 ser368 phosphorylation is reduced at the wound edge and
increased in the proliferating keratinocytes of the epidermal basal
layer [138]. It has been suggested that Cx43 communication com-
partments, generated by selective phosphorylation, are required
at the wound front to ensure correct cellular coordination, prim-
ing cells to proliferate and migrate. The carboxyl tail of Cx43 has
12 serine sites that are known to be phosphorylated by speciﬁc
pathways including PKC (ser368), mitogen-activated protein ki-
nase (MAPK) (ser255, ser279 and ser282) and PKA (ser373) (re-
viewed by [139]). Recent work by Dunn et al. [36], shows that
phosphorylation of Cx43 at ser373 increases dramatically at the
wound edge within 30 min of injury, with a loss of expression
at 24 h, and implies that Akt activation is required for this to oc-
cur. Cx43 ser373 phosphorylation was also shown to abolish ZO-
1 interactions, which may further assist cells in entering a migra-
tory phase [36].
These changes in Cx43 phosphorylation status are likely to be
critical in the transition of epidermal keratinocytes from an adhe-
sive form to a migratory phenotype. The carboxyl tail of Cx43,
unlike the beta connexins, has numerous binding partner pro-
teins, many of which interact with intracellular scaffolding pro-
teins to link with cytoskeletal proteins. Within the epidermis
such interactions are critical to maintain the adhesion junction
nexus status and many studies now recognise that connexins
are central to cell–cell adhesion complexes [140,141]. Of these,
interactions between Cx43 and ZO-1 are particularly important.
The ZO-1 binding site of Cx43 maps to the tip of the carboxyl tail.
Other junctional proteins including E cadherin and tight junction
proteins also interact with ZO-1, providing linkage with alpha
and beta catenin and the actin cytoskeleton [1]. These interac-
tions are central to the maintenance of epidermal barrier
function.
Subtle changes in Cx43 phosphorylation status, as evidenced by
the recent data by Lampe and colleagues, suggest that connexins
can act as sensors during dynamic events such as wound repair
[36]. These sensors enable signalling pathways to be rapidly
switched onto permit cell migration to be activated at both tran-
scriptional and translational control levels. They also dynamically
alter the interaction of connexins with partners of the junctional
nexus including ZO-1. Decreased interaction with ZO-1 reduces
cell to cell adhesion interactions and enables cells to modify their
cytoskeletal dynamics under the inﬂuence of Rac and RhoGTPase
activity [140,142].
Dysregulation of connexin function is thought to play a role in
the failure of wound healing seen in conditions such as diabetes
[14]. Here Cx43, Cx30 and Cx26 expression levels are dramatically
increased at non-healing wound edges, where the cells enter a
state of chronic inﬂammation, hyperproliferation and reduced
migratory capacity [15,143]. Diabetic wounds are at a greater risk
of becoming infected and colonised by pathogens, often resulting
in severe tissue and bone damage, necessitating amputation. Nota-
bly, the skin microﬂora within a diabetic wound is very different to
that in wounds in non-diabetic individuals and the mechanisms by
which these changes inﬂuence innate immune pathways and de-
layed wound healing is now receiving attention [144].
Reducing the elevated Cx43 levels in non-healing conditions
could therefore be beneﬁcial in encouraging wounds to close. This
has led to the development of strategies to target Cx43 expression
and/or function, both of which are showing clear progression to-
wards drug development.
Fig. 2. Changes in Cx43 expression and function occur during wound healing. (Ai–Av) Following scrape-wounding primary mouse keratinocytes (isolated as described by
Kandyba et al. [154]) migrate into the denuded gap. Circle in Av indicates ‘wounded area’ depicted in Ci and Cii. (Bi–Biii) Cells ﬁxed and stained for Cx43 at 0, 3 and 6 h post
wounding illustrate changes in the spatial localisation of Cx43, by 6 h post wounding Cx43 is localised to intracellular areas. (Ci–Cii): Microinjection analysis of keratinocytes
associated with actively migrating keratinocytes exhibit limited transfer of Alexa594 (wounded area) compared to cells behind the wound margin that maintain gap junction
coupling. Other studies revealed this coupling is primarily due to Cx43 [134]. ⁄ = injected cell. Ai–v bar = 100 lm; B: bar = 10 lm C: bar = 20 lm.
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The application of Cx43 antisense oligodeoxynucleotide (asO-
DNs) to skin results in downregulation of Cx43 gene expression
and improves wound healing in a variety of normal and diabetic
animal models [143,145,146]. This approach has now entered clin-
ical trials (http://www.codatherapeutics.com/researchTrials.html)
with initial successful outcomes reported. These asODNs assist
wound healing by increasing cell migration, proliferation and
reducing skin inﬂammation [143,145]. The success of improving
wound healing by asODNs targeting of Cx43 reinforces the funda-
mental role of connexins in this process and opens up other ther-
apeutic avenues.
Although knocking down Cx43 gene expression improves
wound closure, there is substantial evidence (discussed above) that
remodelling Cx43 function and interaction with partner proteins
may also inﬂuence these events. A number of peptide based strat-
egies are proving to have signiﬁcant therapeutic potential. The al-
pha-carboxyl terminus 1 (aCT1) peptide is a 25 amino acid peptide
targeted to the C-terminus of Cx43. It increases skin healing rates
in porcine and murine models [147,148] and in corneal woundsin ‘normal’ and ‘diabetic’ mice [149,150]. The aCT1 peptide binds
in the PDZ domain of ZO-1 and inhibits Cx43-ZO-1 interactions
[151]. The recent reports by Dunn et al. [36], again emphasise
the importance of Cx43 interactions with ZO-1, via adhesive prop-
erties and interaction with the cytoskeleton, in epidermal integrity
and repair [36]. The aCT1 peptide has also now moved into clinical
trials to investigate its translational potential to improve wound
healing (http://ﬁrststringresearch.com/).
Finally, connexin mimetic peptides (CMPs), expressly designed
to target regions on E1 and E2 inhibit connexin function without
altering connexin expression [152,153] represent attractive thera-
peutic entities. The CMPs Gap26 and Gap27 improve cell migration
rates in 2D and 3D organotypic mouse and human in vitro skin
wound models, and in ex vivo porcine wound models
[69,134,137,154,155]. Gap27 shows selectivity to Cx43, and is
effective in keratinocytes taken from diabetic donors, although to
a lesser degree than keratinocytes taken from non-diabetic donors
[69,137,154]. Gap27 may act in several ways to enhance cell
migration in scrape-wounds, by increasing cell migration and pro-
liferation, decreasing cell adhesion, and activating Cx43 ser368
phosphorylation [69,154]. CMPs can inhibit both gap junctional
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lease from hemichannels stimulated by low calcium [154] or by in-
nate immune challenge [106], which may be important in reducing
inﬂammation. Other studies reveal that exposure of dermal ﬁbro-
blasts to Gap27 induces changes in the expression of ECM compo-
nents and cell adhesion genes, again reinforcing roles for connexins
in adhesive interactions that inﬂuence cell migratory responses
[69].
11. Conclusions and future perspectives
It is evident that the complex nature of the epidermal connexin
network serves an important purpose in helping maintain barrier
function. Cx43 is a well-established target to improve wound clo-
sure events. The mechanisms by which Cx43 mediates wound clo-
sure are being revealed using tools that can either knock down
gene expression, interfere with Cx43 interactions with partner pro-
teins or block channel activity. Evidence accumulates that connex-
ins are key sensors to a variety of environmental challenges met by
this air-exposed epidermal barrier. Dissecting mutations in Cx26
and associated epidermal disorders have developed our under-
standing of the functional implications of correctly maintaining
connexin function. It is evident that epidermal calcium gradients
can be modiﬁed by aberrant Cx26 expression, and that over activ-
ity of hemichannels can inﬂuence purinergic signalling pathways
with consequences on a variety of epidermal events including rates
of cell proliferation, differentiation and induction of the innate im-
mune response. That connexin hemichannels are now identiﬁed as
sensors of a diverse array of environmental and internal stimuli,
including pathogens, air, calcium, temperature, and CO2 means
that with our expanding understanding of the roles of these pro-
teins in the epidermis, they are prime for development of new
therapeutic agents that could beneﬁt a diverse range of epidermal
disorders.
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